Genomed (WAR:GEN) Non Operating Income: zł Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:GEN Genomed SA WAR:GEN
79 GF Score
Price zł35.40
GF Value zł36.43
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Genomed Non Operating Income?

Genomed WAR:GEN -6.35% 79 Non Operating Income is zł Mil as of Jun. 2026. GuruFocus rates WAR:GEN with a GF Score™ of 79/100 and a GF Value™ of zł36.43 (Fairly Valued). The stock has 5 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Genomed's Non Operating Income for the three months ended in Jun. 2026 was zł Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was zł Mil.

Genomed Non Operating Income Related Terms

Genomed Non Operating Income Historical Data

* Premium members only.

The historical data trend for Genomed's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomed Non Operating Income Chart

Genomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genomed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
WAR:GEN
79GF Score
Genomed SA WAR:GEN
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomed Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of zł Mil mean?
Genomed (WAR:GEN) has a Non Operating Income of zł Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Genomed and its competitors.
Is Genomed's Non Operating Income too high?
Genomed's current Non Operating Income is zł Mil. Overall, Genomed has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Non Operating Income compare to TMO and DHR?
Genomed's Non Operating Income of zł Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Medical Diagnostics & Research company?
A good Non Operating Income depends on the Medical Diagnostics & Research industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Genomed and its competitors. Genomed's current Non Operating Income is zł Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Fairly Valued. The stock's GF Value™ is zł36.43, compared to a current price of zł35.40 — trading 2.8% below its estimated fair value. The current Non Operating Income is zł Mil. Genomed's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Non Operating Income is zł Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł35.40 is trading 2.8% below its estimated GF Value™ of zł36.43. GuruFocus considers Genomed to be Fairly Valued.

Key valuation signals for WAR:GEN:

  • Non Operating Income: zł Mil
  • GF Value™: zł36.43 vs. price of zł35.40 (2.8% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
79GF Score

Get the complete analysis for WAR:GEN

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł35.40
Price
zł36.43
GF Value